Natasha Deckmann, M.D.
Option Care HealthAbout Natasha Deckmann, M.D.
Independent director of Option Care Health since 2022; age 48; three years of service on the board as of March 18, 2025. She chairs the Quality and Compliance Committee and serves on the Finance & Investment and Nominating & Corporate Governance Committees, bringing clinical leadership, payer/provider expertise, and M&A/risk oversight experience from roles at Tivity Health, Optum, CarePoint Health, and Marsh Inc.
Past Roles
| Organization | Role | Tenure | Committees/Impact |
|---|---|---|---|
| Tivity Health | President; Chief Transformation Officer | 2024–Present (President); 2024 (CTO) | Executive leadership, healthcare technology transformation |
| SecureSeniorConnections | Chief Operating Officer; Chief Clinical Officer; Board Member | 2020–2023 | Clinical oversight; operations in health tech/services |
| CarePoint Health System | Chief Executive Officer | 2018–2020 | Led multi-hospital system and medical groups |
| Optum (UnitedHealth Group) | SVP, Population Health Solutions; COO, Consumer Solutions Group | 2013–2018 | Payer/provider domain; human capital management |
| Marsh Inc. | Positions of increasing responsibility, incl. COO of Marsh International | 2006–2012 | Risk management and governance practices |
External Roles
| Organization | Role | Tenure | Notes |
|---|---|---|---|
| Senior Connect Acquisition Corp. I | Former U.S. public company board member (within last five years) | Not specified | SPAC Board experience |
Board Governance
| Item | Detail |
|---|---|
| Independence | Independent director; board determined standing committee members are independent under Nasdaq/SEC rules |
| Committee Assignments | Quality & Compliance (Chair) ; Finance & Investment (Member) ; Nominating & Corporate Governance (Member) |
| Committee Meetings in 2024 | Q&C: 4 meetings ; Finance & Investment: 5 meetings ; Nominating & Corporate Governance: 5 meetings |
| Board Attendance | Board met 5 times in 2024; each director attended/participated in ≥75% of board and committee meetings during their tenure; all directors attended the 2024 annual meeting |
| Board Leadership | Independent, non-executive Board Chair; separation of Chair and CEO roles; executive sessions at each regular quarterly board meeting; proxy access and overboarding limits in guidelines |
Fixed Compensation
| Component | Amount ($) | Notes |
|---|---|---|
| Board annual cash retainer | 100,000 | Increased from $80,000 to $100,000 for 2024 |
| Quality & Compliance Committee Chair fee | 20,000 | Chair retainer for 2024 |
| Finance & Investment Committee member fee | 5,000 | Member retainer for 2024 |
| Nominating & Corporate Governance Committee member fee | 7,500 | Member retainer for 2024 |
| Reported 2024 fees earned or paid in cash (per proxy) | 132,500 | Deckmann’s total cash/fee line item |
| Meeting fees | None disclosed | Program is retainer-based (cash + RSUs) |
| Deferred compensation plan availability | Eligible; none of the non-employee directors participated in 2024 | Plan adopted in 2023; no director participation in 2024 |
| Expense reimbursement | Reasonable out-of-pocket travel expenses reimbursed | As disclosed |
Performance Compensation
| Feature | Detail |
|---|---|
| Annual director RSU grant value | $160,000; granted May 2024 |
| RSU share determination | $160,000 divided by grant-date closing price; rounded to nearest factor of three |
| Example grant-date price | $30.06 per share (May 15, 2024 grants) |
| Vesting schedule | RSUs vest in equal installments on each of the first three anniversaries of grant date |
| Change-in-control | Vesting accelerates upon change-in-control or termination of service other than for cause |
| Cash retainer taken in RSUs | Deckmann elected to receive annual cash retainers in RSUs: 5,983 RSUs |
| Options | No stock option awards in director program; emphasis on time-based RSUs |
Note: Directors do not receive performance-based equity (no PSUs/TSR metrics). The program emphasizes time-based RSUs to align with shareholder outcomes via stock price movement .
Other Directorships & Interlocks
| Company | Role | Board Committees | Potential Interlock/Conflict |
|---|---|---|---|
| Senior Connect Acquisition Corp. I | Former director | Not disclosed | No OPCH-related transactions disclosed in retrieved sections |
Expertise & Qualifications
- Extensive executive leadership and operational expertise; healthcare technology experience from Tivity and SecureSeniorConnections .
- Payer/provider domain knowledge; clinical oversight; human capital management from Optum and hospital system leadership .
- M&A and business development; P&L integration experience .
- Risk management oversight and governance from Marsh Inc. and board service .
Equity Ownership
| Item | Value |
|---|---|
| Total beneficial ownership (shares) | 5,235; less than 1% of outstanding shares |
| RSUs outstanding as of 12/31/2024 | 11,265 RSUs (includes annual equity award and RSUs from cash retainer election) |
| Hedging/pledging | Company policy prohibits short sales, hedging, and pledging by directors |
| Director stock ownership guidelines | Retain 75% of net shares (including unvested RSUs) until ownership equals 3× the annual cash retainer; all directors were in compliance as of 12/31/2024 |
Governance Assessment
- Board effectiveness: Deckmann chairs Quality & Compliance, directly overseeing compliance, legal/regulatory risk, patient safety, and information security—critical for an infusion services provider subject to reimbursement and clinical quality scrutiny . Her payer/provider and clinical background strengthens oversight quality and cross-committee risk linkage .
- Independence and engagement: Independent since 2022; serves on two additional committees; board attendance meets or exceeds company standard; present at the annual meeting—signals solid engagement .
- Compensation alignment: Mix emphasizes equity via time-based RSUs ($160,000 annual grant; three-year vesting), with role-based cash retainers; she elected to take cash retainers in RSUs (5,983 RSUs), increasing alignment with shareholder outcomes and reducing cash preference .
- Ownership and policies: Beneficial ownership is modest (5,235 shares; <1%), but RSUs outstanding (11,265) and compliance with robust stock ownership/retention guidelines mitigate alignment concerns; hedging/pledging prohibited—a governance positive .
- Conflicts/related-party: No related-party transactions involving Deckmann are disclosed in the retrieved sections; the Audit Committee reviews and must approve transactions above $120,000 with related parties—policy reduces conflict risk .
- RED FLAGS: None disclosed in the retrieved sections specific to Deckmann (no pledging, no attendance shortfall, no related-party transactions noted). Monitor external executive workload (Tivity Health leadership) against OPCH overboarding limits and committee responsibilities; guidelines include overboarding restrictions .